Top Biotech Companies (3,709)
Covestro is one of the world’s leading manufacturers of high-quality polymer materials and their components. With its innovative products, processes and methods, the company helps enhance sustainability and the quality of life in many areas. Covestro supplies customers around the world in key industries such as mobility, building and living, as well as the electrical and electronics sector. In addition,...
Covestro's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests Covestro holds top-tier, often #1, positions in polycarbonate and select specialty coating precursors, underpinned by global, multi-site capacity. Evidence also points to recognized strategic importance and deep technology/application know-how across polyurethane inputs, even if not the largest in every sub-market.
Future-Ready Strategy: Feedback suggests the company has clear climate-neutrality and circularity targets and is executing a multi-year transformation program alongside selective specialty acquisitions. These actions aim to shift the mix toward higher-value applications and position the portfolio for recovery when pricing and demand normalize.
Investor Backing & Capital Strength: Feedback suggests majority ownership by ADNOC/XRG and a completed capital increase provide stronger financial backing and optionality for investment. Regulatory clearances and integration steps indicate committed sponsorship that could support medium-term growth initiatives.
Piramal Pharma Limited is a global pharmaceutical company that provides end-to-end drug development and manufacturing services (CDMO), complex hospital generics, and consumer healthcare products.
Alphazyme was founded in 2018 by Christopher Benoit, Stephana Petrino and Chad Decker. Our experienced team has a track record of success and a passion for supporting molecular biology innovators. Our mission is to be the world’s premier partner for custom, industrial-scale, molecular biology enzymes. We are enzyme development and production experts, and partner with the manufacturers of nucleic acid therapies and...
KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 500+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP...
KBI Biopharma's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests KBI’s integrated Selexis-enabled CLD, analytics depth, and end-to-end biologics services provide a specialist edge among mid-tier CDMOs. Successful 2024 FDA inspection and an expanded commercial contract signal credibility beyond early clinical stages.
Strategic Partnerships: Operational consolidation with Selexis and alliances such as Argonaut and Infinimmune indicate a deliberate partner strategy to broaden drug substance-to-drug product solutions. These moves position KBI to compete for larger, longer-term programs.
Customer Loyalty & Retention: The extension and expansion of a commercial manufacturing agreement with a leading pharma through 2029, with roughly $250M in additional purchases, points to durable demand from key customers. This multi-year commitment underscores continuity from early work into commercial supply.
Rocky Mountain Laboratories LLC (also known as Rocky Labs) is a medical laboratory testing company founded in 2022. It specializes in advanced diagnostic offerings and promotes responsible, medically necessary testing, particularly in infectious diseases. The company provides clinical laboratory services and maintains multiple facilities across the United States, including sites in Utah, Nevada, Idaho, Colorado, Arizona, and Texas.
Ethos Holding Corp. (dba Ethos Laboratories) operates a CAP‑accredited, CLIA‑certified, high‑complexity clinical laboratory that provides diagnostic and toxicology testing, biomarker and medical specimen analyses, and research collaborations focused on pain‑management diagnostics. Ethos supplies clinical testing services (including PCR and therapeutic monitoring) to healthcare providers and maintains R&D efforts to advance laboratory diagnostic tools.
Genus is a world-leading animal genetics company. At the forefront of innovation in gene-editing, advanced reproductive biology, and other breakthrough breeding technologies, Genus R&D advances an agricultural practice thousands of years old – animal breeding. Our goal is to ensure the global food system continues to nurture healthy, productive animals that yield affordable, high-quality proteins for a sustainable future. We believe...
Johnson County Clin-Trials (JCCT) is a full-service clinical research site specializing in Phase I-IV outpatient and inpatient trials, providing excellence in study recruitment, clinical research, medical care, and data accuracy for pharmaceutical and biotechnology companies.
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company’s pipeline include a menin inhibitor for R/R acute leukemia and a monoclonal antibody that blocks the CSF-1 receptor for chronic graft-versus-host disease. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and...
Syndax Pharmaceuticals's Top Stability & Growth Strengths
Strong Market Position & Advantage: First-in-class approvals for Revuforj across two acute leukemia subtypes and NCCN inclusion, together with Niktimvo’s novel CSF-1R mechanism in cGVHD, position the company at the forefront of these niches. First-mover status and rapid guideline uptake underpin a durable competitive foothold.
Strong Revenue Growth: Reported revenue increased sequentially in 2025 with rising Revuforj prescriptions and growing collaboration revenue from Niktimvo, signaling early commercial traction. Multiple new approvals and label expansions during 2024–2025 further supported the ramp.
Strategic Partnerships: Co-commercialization with Incyte enhances market penetration in cGVHD, and the World Orphan Drug Alliance program expands access to Revuforj globally. These alliances bolster commercial reach and operational execution.
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than...
Ferring Pharmaceuticals's Top Stability & Growth Strengths
Strong Revenue Growth: 2025 revenues exceeded €2.5 billion, rising versus 2024 with notable momentum in the U.S. and key contributions from Menopur and Adstiladrin. Company disclosures and the annual report indicate continued year-over-year top-line expansion.
Innovation-Driven Growth: First-in-class approvals (Rebyota in microbiome therapeutics and Adstiladrin in bladder-cancer gene therapy) and WHO-recognized maternal-health innovation (heat-stable carbetocin) demonstrate differentiated science translating into commercial progress. FDA clearance of a second U.S. Adstiladrin site supports scaling these innovations.
Strong Market Position & Advantage: Leadership in ART/fertility and first-mover status in microbiome therapeutics and intravesical gene therapy provide competitive advantages in defined niches. This positioning underpins recent growth in core franchises.
Bracco is an international Group active in the healthcare sector and a leader in diagnostic imaging. It has around 3,700 employees and annual total consolidated revenues of around 1,7 billion euros, 89% of which from international sales. In the R&D area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors. The Group’s main...
At Ironwood Pharmaceuticals, we are committed to advancing the treatment of GI diseases and redefining the standard of care for GI patients. As a pioneer and champion in the development of a market-leading therapy for IBS-C and CIC, we are singularly focused on advancing the treatment of GI diseases and continue to challenge what has been done before to shape...
Nomic (formerly nplex biosciences) is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. We are building the nELISA, a next-generation ELISA platform for measuring proteins at scale and at high throughput. The nELISA was designed to seamlessly integrate into current workflows in biology and is uniquely adaptable to a wide...
At PathAI our mission is to improve patient outcomes with AI-powered technology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.
Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases.
Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology. By applying these insights, we believe we have a differentiated approach...
The Allen Institute is a 501(c)(3) nonprofit medical research organization dedicated to accelerating science for a healthier world. Through large-scale, multidisciplinary research initiatives, the Institute generates foundational knowledge, data, tools, and models that are shared openly with the world to advance our understanding of life and health, focusing on the brain, cells, and immune system to transform human health.
AbSci is a leading synthetic biology company that translates ideas into drugs with a platform technology that reinvents the biopharmaceutical drug discovery process.
Asklepios BioPharmaceutical, Inc. (AskBio) is a leading clinical-stage adeno-associated virus (AAV) gene therapy company dedicated to improving the lives of patients with rare disorders and other diseases. We’ve built a foundation of therapeutic programs, AAV manufacturing and a rich portfolio of patented technology. Our therapeutic focus includes neuromuscular, central nervous system, cardiovascular and metabolic diseases with clinical trials underway for Pompe...
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. Founded in 2017, SpringWorks has a diversified targeted oncology pipeline spanning solid tumors and hematological cancers, including clinical trials in rare tumor types and highly prevalent, genetically defined cancers
